Arrowstreet Capital’s Regenxbio RGNX Stock Holding History

Arrowstreet Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,200	Closed	-$770K	–	1477
2018 Q3	$770K	Buy	+10,200	New	+$735K	﹤0.01%	844

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arrowstreet Capital's RGNX Position: Q4 2018 in Review

Arrowstreet Capital sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 10,200 shares — an estimated $770K sold.

Arrowstreet Capital first reported a position in RGNX in Q3 2018 and held it in 1 quarter. The position peaked at $770K in Q3 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

Arrowstreet Capital reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
Arrowstreet Capital sold 10,200 Regenxbio shares in Q4 2018, an estimated $770K.
Arrowstreet Capital first reported a position in Regenxbio in Q3 2018 and held it in 1 quarter.
Arrowstreet Capital's Regenxbio position peaked at $770K in Q3 2018.
183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Arrowstreet Capital's 13F filing for Q4 2018, filed 14 Feb 2019.